Related Experiment Video
Updated: Aug 16, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
The involvement of glutamate in the pathophysiology of depression
1Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. nfpaluch@cyf-kr.edu.pl
Abstract:
In spite of more than 40 years of thorough studies, conventional antidepressants still have many limitations that hinder the effective treatment of depression. It seems that a breakthrough in the therapy of depression will require going beyond a monoamine-based theory of depression. Converging lines of evidence indicate that the glutamatergic system might be a promising target for a novel antidepressant therapy. Both ionotropic glutamate receptor ligands (functional NMDA receptor antagonists and AMPA receptor potentiators) and compounds acting at metabotropic glutamate receptors (mGluRs; group I mGluR antagonists, group II antagonists and group III agonists) produce antidepressant-like activity in several preclinical and some clinical studies. In this review, current knowledge and crucial hypotheses concerning the role of glutamate in the pathophysiology of depression are discussed.
Related Concept Videos
Depression: Overview
G-protein Coupled Receptors
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Antiepileptic Drugs: Glutamate Antagonists
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
